21st European Charcot Foundation Meeting


Published on

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

21st European Charcot Foundation Meeting

  1. 1. 21st Annual Meeting of the European Charcot Foundation BAVENO, Italy NOV. 28 – 30, 2013 Personalised Medicine Where we are with multiple sclerosis? November 28, 2013 14.00 – 15.00 IXX ECF LECTURE Chair: O.R. Hommes – G. Comi Personalised treatment in MS is it relevant for patients? P.S. Sorensen 15.00 – 16.40 SESSION I: Rationale Chair: H. Wekerle The future of technologies for personalised medicine E. Stupka The lesson of cancer C. Ruiz Genetic and environmental complexity in MS A. Compston Where are we with the pathological MS subtypes? H. Lassmann 16.40 – 17.00 COFFEE BREAK 17.00 – 18.30 SATELLITE SYMPOSIUM SPONSORED BY GENZYME New options to improve the personalized approach in MS Chair: G. Comi Window of opportunity in MS treatment with Teriflunomide G. Edan Window of opportunity in MS treatment with Alemtuzumab K. Selmaj Improve the personalized approach in MS O.R. Hommes Faculty discussion 18.30 – 19.30 WELCOME RECEPTION
  2. 2. November 29, 2013 8.30 – 10.10 SESSION II: MS variability and prognostic implications Chair: M. Filippi Clinical prognostic factors G. Ebers Conventional MRI F. Fazekas Non conventional D. Miller Laboratory G. Giovannoni 10.10 – 10.30 COFFEE BREAK 10.30 – 12.10 SESSION III: Is it possible to predict and to monitor the response to the treatment? Chair: M. Clanet Problems and pitfall in assessing treatment response M. Tintoré Role of biomarkers H.P. Hartung Pharmacogenetic and pharmacogenomic M. Comabella The contribution of post marketing studies M. Trojano 12.10 – 13.30 SATELLITE SYMPOSIUM SPONSORED BY TEVA Keeping focus - Considerations for a patient-centric management of MS Chairs: G. Edan – G. Giovannoni Managing the impact of MS – A patient perspective C. Devine Beyond ARR and EDSS – How meaningful are established clinical parameters to patients? P.S. Sorensen Towards improved care in MS – How can treatments better address patient needs? T. Ziemssen 13.30 – 14.30 LUNCH
  3. 3. 14.30 – 16.10 SESSION IV: Treatments and algorithms Chair: K. Selmaj Efficacy – convenience of MS treatments X. Montalban Lesson from the NMO/MS treatment comparison J. Palace When to start, when to shift, when to stop M. Freedman Algorithms G. Comi 16.10 – 16.30 COFFEE BREAK 16.30 – 18.00 SESSION V: Challenges Chair: G. Edan Patient perspective A. Solari Adherence O. Fernandez Present and future pregnancies S. Vukusic MS centre organization L. Kappos 18.00 – 18.30 SATELLITE SYMPOSIUM SPONSORED BY ALMIRALL Endocannabinoid system modulation to improve resistant MS spasticity O. Fernandez
  4. 4. November 30, 2013 8.30 – 10.10 SESSION VI : Medical Agency, Pharma Industries and Social Security System: the challenge of new MS Treatments Chair: A. Thompson The European Medical Agency approach in the evaluation of MS treatments L. Massacesi Pharma company B. Musch Social security system F. Lega Economic aspects of innovative treatments L. Mantovani 10.10 – 10.30 COFFEE BREAK 10.30 – 12.10 SESSION VII: Round table + general discussion: the MS centres experience Chair: A. Boyko Barcelona M. Tintoré Milan V. Martinelli Ottawa M. Freedman Japan K. Fujihara 12.10 – 13.30 YOUNG INVESTIGATOR AWARDS & CONCLUDING REMARKS G. Comi – P.S. Sorensen 13.30 – 14.30 LUNCH